Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Discover 8 key causes of bloody cough from infections to lung conditions. Learn when coughing blood needs medical attention ...

If you're struggling with a chronic cough, it may be linked to several illnesses that are on the rise, according to public health providers.

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant ...

Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares and lifted the price target ...

We are looking forward to the results from our Phase 2b trial in IPF patients with chronic cough to finalize the development path forward for both indications," said James Cassella, Ph.D., Chief ...

Haduvio, which acts both centrally and peripherally, is the first investigational therapy to show a significant reduction in cough frequency in clinical trials for IPF chronic cough and RCC patients.

Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an ...

Jonathan Toews' journey back to the NHL included a trip to India for an eastern detoxification regimen. John Doherty ...

Berenberg has lowered its rating on GSK plc (LON: GSK) to Hold from Buy, a move driven by the stock’s strong year-to-date ...

This is the first study to comprehensively evaluate children with chronic cough and without a selective workup. Our study suggests that among children with chronic cough (ie, cough of > 8 weeks ...

Learn 5 effective methods to reverse airway reflux damage. Natural healing approaches, dietary changes, and treatments that ...